Why the study?
Studies investigating the association between the AGTR1 gene A1166C polymorphism and cancer risk have yielded inconclusive results.
Is the AGTR1 gene A1166C polymorphism associated with an increased risk of cancer?
Is the AGTR1 gene A1166C polymorphism associated with an increased risk of cancer?
The AGTR1 gene A1166C polymorphism does not appear to be associated with an increased risk of cancer.
AGTR1 A1166C-cancer link remains inconclusive; leaves open larger prospective studies before any clinical consideration.
OBJECTIVE:: The association between angiotensin II type 1 receptor ( AGTR1) gene A1166C polymorphism and cancer risk has been investigated in many studies. However, the results have been inconclusive. A meta-analysis was performed to obtain a more precise estimation of the relationship. METHODS:: The PubMed and China National Knowledge Infrastructure databases were searched for published literature. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strengths of association. RESULTS:: Ten studies, including 1553 patients and 1904 controls, were included in the meta-analysis. Overall, there were no significant associations between the AGTR1 gene A1166C polymorphism and cancer risk in the general population (CC vs AA: OR = 1.09, 95% CI = 0.50-2.37; AC vs AA: OR = 1.54, 95% CI = 0.81-2.91; dominant model: OR = 1.46, 95% CI = 0.77-2.79; recessive model: OR = 1.12, 95% CI = 0.84-1.49). In a subgroup analysis by nationality and cancer type, the results also showed no association between this polymorphism and cancer risk. CONCLUSIONS:: This meta-analysis demonstrated that the AGTR1 gene A1166C polymorphism does not appear to be related to the risk of cancer.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: